Rafael Holdings ( (RFL) ) has released its Q4 earnings. Here is a breakdown of the information Rafael Holdings presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage pharmaceutical and medical device companies. The company’s lead candidate, Trappsol® Cyclo™, is undergoing a pivotal Phase 3 clinical trial for treating Niemann-Pick Disease Type C1, a rare genetic disorder.
In its latest earnings report, Rafael Holdings announced its financial results for the fourth quarter and full fiscal year 2025. The company highlighted the progress of its Phase 3 clinical trial for Trappsol® Cyclo™ and the successful completion of a $25 million rights offering to strengthen its financial position.
Key financial metrics revealed a net loss of $12.1 million for the fourth quarter, compared to a $4.5 million loss in the same period last year, attributed to increased research and development expenses following the acquisition of Cyclo Therapeutics. For the full fiscal year, the net loss was $30.5 million, an improvement from the previous year’s $34.4 million loss, due to gains from investments and the consolidation of new acquisitions.
Research and development expenses significantly increased to $12.8 million for the year, reflecting the company’s strategic focus on advancing its clinical trials and integrating new acquisitions. General and administrative expenses also rose, driven by the consolidation of Cyclo Therapeutics and other entities.
Looking ahead, Rafael Holdings aims to continue advancing its clinical programs and exploring new opportunities to drive value for stakeholders, leveraging its strengthened financial position and recent strategic appointments.